Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice

被引:36
作者
Beckhove, P [1 ]
Schütz, F
Diel, IJ
Solomayer, EF
Bastert, G
Foerster, J
Feuerer, M
Bai, LH
Sinn, HP
Umansky, V
Schirrmacher, V
机构
[1] German Canc Res Ctr, Tumor Immunol Program, Div Cellular Immunol, D-69120 Heidelberg, Germany
[2] Univ Hosp, Dept Obstet & Gynecol, Heidelberg, Germany
[3] German Canc Res Ctr, Cooperat Unit Dermatooncol, D-6900 Heidelberg, Germany
关键词
NOD/Scid mice; cellular adoptive transfer; breast cancer xenotransplantation; tumor-infiltrating lymphocytes; graft-vs.-host disease;
D O I
10.1002/ijc.11125
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We describe a new human tumor xenotransplant animal model that is highly efficient for engraftment, does not need host conditioning and is suitable for in vivo studies of human tumors. Pieces of 61 freshly operated primary breast tumors were implanted into 172 irradiated and 228 nonconditioned NOD/Scid mice. A high mortality was observed in irradiated but not in nonconditioned recipients. More than 90% of analyzed implanted breast cancer specimens engrafted in the NOD/Scid mice irrespective of pretreatment. The tumors were vascularized within 3 days of implantation and maintained original histomorphology as well as expression patterns of tumor markers (cytokeratin and MUCI) and cytokines (tumor necrosis factor alpha (TNF-alpha), interleukin-4 (IL-4) and IL-10) released by adjacent stromal cells. A majority of tumors grew slowly, locally infiltrating host tissue, whereas some grew aggressively, developing large, fatal tumor masses and metastases within regional lymph nodes. Tumor progression in mice correlated with stage, grade, proliferation index and hormone receptor status of primary tumors. The reproducible growth behavior and preservation of characteristic features suggest that this new xenotransplant model is relevant and can be recommended for testing new anticancer therapies. (C) 2003 Wiley-Liss. Inc.
引用
收藏
页码:444 / 453
页数:10
相关论文
共 59 条
[1]   ENHANCEMENT OF EPIDERMAL GROWTH-FACTOR RECEPTOR EXPRESSION ON GLIOMA-CELLS BY RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA [J].
ADACHI, K ;
BELSER, P ;
BENDER, H ;
LI, DR ;
RODECK, U ;
BENVENISTE, EN ;
WOO, D ;
SCHMIEGEL, WH ;
HERLYN, D .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1992, 34 (06) :370-376
[2]   SELECTIVE INTERACTIONS BETWEEN MAMMARY EPITHELIAL-CELLS AND FIBROBLASTS IN COCULTURE [J].
ADAM, L ;
CREPIN, M ;
LELONG, JC ;
SPANAKIS, E ;
ISRAEL, L .
INTERNATIONAL JOURNAL OF CANCER, 1994, 59 (02) :262-268
[3]  
Alpaugh ML, 1999, CANCER RES, V59, P5079
[4]  
Amadori A, 1996, Semin Immunol, V8, P249, DOI 10.1006/smim.1996.0031
[5]   CYTOKINES - COORDINATORS OF IMMUNE AND INFLAMMATORY RESPONSES [J].
ARAI, K ;
LEE, F ;
MIYAJIMA, A ;
MIYATAKE, S ;
ARAI, N ;
YOKOTA, T .
ANNUAL REVIEW OF BIOCHEMISTRY, 1990, 59 :783-836
[6]  
BALKWILL FR, 1991, CYTOKINES CANC THERA, P17
[7]   Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies [J].
Bankert, RB ;
Egilmez, NK ;
Hess, SD .
TRENDS IN IMMUNOLOGY, 2001, 22 (07) :386-393
[8]   Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies [J].
Brossart, P ;
Heinrich, KS ;
Stuhler, G ;
Behnke, L ;
Reichardt, VL ;
Stevanovic, S ;
Muhm, A ;
Rammensee, HG ;
Kanz, L ;
Brugger, W .
BLOOD, 1999, 93 (12) :4309-4317
[9]   Approaches to dendritic cell-based immunotherapy after peripheral blood stem cell transplantation [J].
Brugger, W ;
Brossart, P ;
Scheding, S ;
Stuhler, G ;
Heinrich, K ;
Reichardt, V ;
Grünebach, F ;
Bühring, HJ ;
Kanz, L .
HEMATOPOIETIC STEM CELLS: BIOLOGY AND TRANSPLANTATION, 1999, 872 :363-371
[10]   In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy [J].
Cao, H ;
Vergé, V ;
Baron, C ;
Martinache, C ;
Leon, A ;
Scholl, S ;
Gorin, NC ;
Salamero, J ;
Assari, S ;
Bernard, J ;
Lopez, M .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (02) :183-194